These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37413879)

  • 1. Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid X receptor agonists.
    Wang W; Cao Z; Yang Z; Chen Y; Yao H; Zhou D; Ou P; Huang W; Jiao S; Chen S; Chen L; Liu Y; Mao J; Xie J; Xiang R; Yang Y; Chen Y; Yang Y; Tan L; Tang H; Zhang L; Li Z
    Eur J Med Chem; 2023 Oct; 258():115614. PubMed ID: 37413879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
    Zhu Y; Zhang J; Min F; Yang X; Li L; Zhang Y; Hou X; Fang H
    Bioorg Med Chem Lett; 2022 Nov; 76():128993. PubMed ID: 36130662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and structure-activity relationship studies of novel partial FXR agonists for the treatment of fatty liver.
    Qiu Q; Wang W; Zhao X; Chen Y; Zhao S; Zhu J; Xu X; Geng R
    Bioorg Chem; 2020 Nov; 104():104262. PubMed ID: 32919135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist.
    Hu L; Ren Q; Deng L; Zhou Z; Cai Z; Wang B; Li Z
    Eur J Med Chem; 2021 Feb; 211():113106. PubMed ID: 33360559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease.
    Qin T; Gao X; Lei L; Feng J; Zhang W; Hu Y; Shen Z; Liu Z; Huan Y; Wu S; Xia J; Zhang L
    Eur J Med Chem; 2023 Apr; 252():115307. PubMed ID: 37003047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR and Molecular Dynamics Study of Isoxazole Derivatives to Identify the Structural Requirements for Farnesoid X Receptor (FXR) Agonists.
    Yan D; Yang Y; Shen H; Liu Z; Yao K; Liu Q
    Molecules; 2024 Mar; 29(6):. PubMed ID: 38542850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis.
    Mo C; Xu X; Zhang P; Peng Y; Zhao X; Chen S; Guo F; Xiong Y; Chu XJ; Xu X
    J Med Chem; 2023 Jul; 66(14):9363-9375. PubMed ID: 37424079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease.
    Huang W; Cao Z; Wang W; Yang Z; Jiao S; Chen Y; Chen S; Zhang L; Li Z
    Bioorg Chem; 2024 Feb; 143():107071. PubMed ID: 38199141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Structural Optimization of Dual FXR/PPARδ Activators.
    Schierle S; Neumann S; Heitel P; Willems S; Kaiser A; Pollinger J; Merk D
    J Med Chem; 2020 Aug; 63(15):8369-8379. PubMed ID: 32687365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hammerhead-type FXR agonists induce an enhancer RNA
    Chen J; Wang R; Xiong F; Sun H; Kemper B; Li W; Kemper J
    Elife; 2024 Apr; 13():. PubMed ID: 38619504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
    Flesch D; Gabler M; Lill A; Gomez RC; Steri R; Schneider G; Stark H; Schubert-Zsilavecz M; Merk D
    Bioorg Med Chem; 2015 Jul; 23(13):3490-8. PubMed ID: 25934227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 4-aminophenylacetamide derivatives as intestine-specific farnesoid X receptor antagonists for the potential treatment of nonalcoholic steatohepatitis.
    Chen C; Zhang B; Tu J; Peng Y; Zhou Y; Yang X; Yu Q; Tan X
    Eur J Med Chem; 2024 Jan; 264():115992. PubMed ID: 38043493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knocking on FXR's door: the "hammerhead"-structure series of FXR agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities.
    Gege C; Kinzel O; Steeneck C; Schulz A; Kremoser C
    Curr Top Med Chem; 2014; 14(19):2143-58. PubMed ID: 25388536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational study of novel natural agonists targeting farnesoid X receptor.
    Hu X; Ge J; Wen Y
    Sci Rep; 2024 Jul; 14(1):17597. PubMed ID: 39079973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator.
    Luo G; Lin X; Li Z; Xiao M; Li X; Zhang D; Xiang H
    Eur J Med Chem; 2021 Jan; 209():112910. PubMed ID: 33049605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural optimization and biological evaluation of 1-adamantylcarbonyl-4-phenylpiperazine derivatives as FXR agonists for NAFLD.
    Qin T; Gao X; Lei L; Zhang W; Feng J; Wang X; Shen Z; Liu Z; Huan Y; Wu S; Xia J; Zhang L
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114903. PubMed ID: 36375336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
    J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis.
    Cao S; Yang X; Zhang Z; Wu J; Chi B; Chen H; Yu J; Feng S; Xu Y; Li J; Zhang Y; Wang X; Wang Y
    Eur J Med Chem; 2022 Feb; 230():114089. PubMed ID: 34998040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of Novel Farnesoid X Receptor Agonists and Validation of Their Efficacy in Activating Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Osteoblasts.
    Fujimori K; Iguchi Y; Yamashita Y; Gohda K; Teno N
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31744088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.